ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
Mar 27 2019

Enterome to present data on its innovative microbiome-derived molecular mimicry approach to cancer immunotherapy at AACR 2019

Paris, France and Cambridge, MA, USA – March 27, 2019

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, announces it will present data on its innovative microbiome-based approach for the development of therapeutic peptide cancer vaccines for the first time in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA, USA (March 29 to April 3).

Enterome’s innovative approach is based on the concept of “molecular mimicry” whereby microbiome-derived bacterial antigens show molecular similarity with Tumor-associated Antigens (TAAs) and Tumor-specific Neoantigens (TSNAs). Based on this similarity, bacterial antigens (“onco-mimics”) mimic key tumor antigens that are highly expressed by tumors to trigger tumor-specific cytotoxic T cell immune responses.

Enterome has developed a proprietary discovery platform to identify such bacterial onco-mimics from the human gut microbiome. The data to be presented at AACR 2019 demonstrate that onco-mimics identified by Enterome elicited strong immune responses against self-peptides that were, by themselves, not immunogenic. While mice vaccinated with TAAs did not generate an immune response, vaccination with onco-mimics were observed to result in a strong immune response against both bacterial peptides and selected TAAs. Furthermore, adoptive transfer of T cells from mice immunized with onco-mimics into tumor-engrafted nude mice led to tumor control in the presence of checkpoint inhibitors.

Dr. Christophe Bonny, CSO of Enterome, commented: “We are very excited by these data that we believe represent an early validation of our innovative approach to cancer immunotherapy. It is now well recognized that the gut microbiome plays an important role in driving the development of T cells and the presence of commensal-specific memory T-cells. We believe our approach, based on bacterial molecular mimicry, has the potential to open up opportunities to develop new targeted therapies against tumor cells that are not detected as non-self by the immune system.”

Enterome’s first product candidate developed using its molecular mimicry approach, EO2401, comprises three onco-mimics that are highly homologous to solid tumor antigens. Enterome expects to initiate a Phase 1b/2a clinical trial of EO2401 in 2019 as a potential new immunotherapy for glioblastoma multiforme (GBM), for which no curative treatments exist.

The presentation details are:

  • Poster title: Microbiome derived peptides stimulate strong immune response against tumor associated antigens and trigger in vivo tumor regression after vaccination
  • Session Title: Cancer Vaccines and Intratumoral Immunomodulation
  • Abstract ID#: 1475 (poster board 30)
  • Poster presentation: April 1, 8 am – 12 pm EST, Georgia World Congress Center, Exhibit Hall B, Poster Section 22

The abstract is available online – click here.

 

top-header

Download the press release (.pdf format)

pr-en

Comments are closed.

Categories

  • PRESS RELEASES
  • PRESS RELEASES 2020
  • PRESS RELEASES 2019
  • PRESS RELEASES 2018
  • PRESS RELEASES 2017
  • PRESS RELEASES 2016
  • PRESS RELEASES 2015
  • PRESS RELEASES 2014
  • CAREERS
  • PRESS
ETEROME-Bioscience

ENTEROME

94/96 avenue Ledru-Rollin
75011 PARIS, FRANCE
Tel : +33 (0)1 75 77 27 85
Email : info@enterome.com

INFORMATIONS

RCS Paris N° 508 580 289
Siret : 50858028900025
NAF : 7211Z
N° TVA : FR40 508 580 289

Legal notice • Privacy Policy • Cookie Policy
2021 ENTEROME — All rights reserved.
Lors de votre navigation sur notre site internet, nous sommes susceptibles de déposer des cookies sur votre appareil à des fins d’analyses et de performances. Vous avez la possibilité d’accepter, de refuser ou de paramétrer le dépôt de cookies.

When you navigate on our website, we may deposit cookies on your device for analysis and performance purposes. You are able to accept, refuse or configure the cookies' deposit. [ Read More ]

Cookie settings Reject Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Read more about our Privacy Policy.
Necessary
Always Enabled

The cookies defines under this category are absolutely essential for the website to function. Hence they are loaded by default irrespective if user consent.

CookieDescription
cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-non-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Non Necessary".
PHPSESSIDThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytics

Analytics cookies help us understand how our visitors interact with the website. It helps us understand the number of visitors, where the visitors are coming from, and the pages they navigate. The cookies collect this data and are reported anonymously.

CookieDescription
_gaThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gidThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works.

CookieDescription
_gatThis cookies is installed by Google Universal Analytics to throttle the request rate to limit the colllection of data on high traffic sites.